Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

α-Neebisin derivatives and their preparation methods and applications

A technology of azadirachtin and derivatives, applied in the field of medicine, can solve the problems of difficult to achieve therapeutic effect, no effect of treating cerebral infarction or vascular dementia, etc., and achieve high safety, good therapeutic effect, and the effect of reducing toxicity

Active Publication Date: 2020-11-13
上海如凌生物医药有限公司
View PDF11 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Based on the fact that the etiology of cerebral infarction and vascular dementia has a greater correlation with vascular lesions, rather than a single factor causing nerve cell damage, it is difficult to achieve a good therapeutic effect by targeting a single factor. For example, some compounds have neuroprotective effects or Antioxidant, but does not have the effect of treating cerebral infarction or vascular dementia

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • α-Neebisin derivatives and their preparation methods and applications
  • α-Neebisin derivatives and their preparation methods and applications
  • α-Neebisin derivatives and their preparation methods and applications

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] Embodiment 1: the synthesis (synthetic route figure such as figure 1 shown)

[0039]

[0040] Take α-Neebisin (40mg, 0.1mmol) in toluene solution, stir until dissolved, the solution turns yellow at this time, add 2,3-dichloro-5,6 dicyanoquinone (DDQ, 45mg, 0.2mmol) , reacted at 40°C, detected by TLC during the reaction, the reaction was completed after 5 hours, the toluene was distilled off under reduced pressure, separated and purified by silica gel column chromatography, and the yellow solid compound HZA was obtained with a yield of 85%.

[0041] Weigh BTC (60mg, 0.202mmol) into a 25mL two-necked bottle, add 5mL of anhydrous dichloromethane, stir magnetically, add equivalent N-methylaniline, triethylamine (0.25mmol) and Add 5mL of dichloromethane slowly in an ice bath, remove the ice-salt bath after the addition, and stir at room temperature for 4 hours.

[0042] Add HZA (40mg, 0.1mmol) to a 10ml single-necked bottle, add a trace of DMAP, 5mL of dichloromethane, ...

Embodiment 2

[0044] Embodiment 2: the synthesis (synthetic route figure such as figure 1 shown)

[0045]

[0046] The synthetic method of compound HZA is the same as above.

[0047] Weigh BTC (58mg, 0.2mmol) into a 25mL two-necked bottle, add 5mL of anhydrous dichloromethane, stir magnetically, add an equivalent amount of N-ethylaniline, triethylamine (0.25mmol) and Add 5mL of dichloromethane slowly in an ice bath, remove the ice-salt bath after the addition, and stir at room temperature for 4 hours.

[0048] Add HZA (40mg, 0.1mmol) to a 10ml single-necked bottle, add a trace of DMAP, 5mL of dichloromethane, and stir magnetically at room temperature until completely dissolved. Slowly add the solution dropwise to the reaction solution in the previous step under the ice-salt bath, remove the ice-salt bath after the dropwise addition, and stir at room temperature. After the reaction is completed, add 3 to 6 times the volume of distilled water to the above reaction solution, then extract...

Embodiment 3

[0050] Embodiment 3: the synthesis (synthetic route figure such as figure 1 shown)

[0051]

[0052] The synthetic method of compound HZA is the same as above.

[0053] Weigh BTC (58mg, 0.2mmol) into a 25mL two-necked bottle, add 5mL of anhydrous dichloromethane, stir magnetically, add an equivalent amount of N-methyl-o-methylaniline, triethylamine (0.25 mmol) and 5mL of dichloromethane were slowly added dropwise in an ice bath, and the ice-salt bath was removed after the dropwise addition, and stirred at room temperature for 4h.

[0054] Add HZA (40mg, 0.1mmol) to a 10ml single-necked bottle, add a trace of DMAP, 5mL of dichloromethane, and stir magnetically at room temperature until completely dissolved. Slowly add the solution dropwise to the reaction solution in the previous step under the ice-salt bath, remove the ice-salt bath after the dropwise addition, and stir at room temperature. After the reaction is completed, add 3 to 6 times the volume of distilled water t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides an α-mangostin derivative having a structure of general formula I, a preparation method thereof, and an application of the same in preparing a drug for treating a brain injury caused by ischemia, such as vascular dementia and cerebral infarction. The vascular dementia is learning and memory impairment induced by a vascular disease or brain ischemia or cell loss in the dentate gyrus of the hippocampus.

Description

technical field [0001] The present invention relates to α-azadirin derivatives, a preparation method of α-azadirin derivatives, and the application of α-azadirin derivatives in the preparation of drugs for treating ischemic brain injury, and belongs to the invention in the technical field of medicine. Background technique [0002] Brain diseases caused by vascular lesions have become a serious threat to health, especially with the increasing number of elderly people in China, this problem has become more prominent. Cerebral infarction refers to ischemic necrosis or encephalomalacia of limited brain tissue caused by cerebral blood supply disturbance, ischemia, and hypoxia. The common clinical types of cerebral infarction include cerebral thrombosis, lacunar infarction, and cerebral embolism. , Cerebral infarction accounts for 80% of all strokes. Vascular dementia (vascular dementia, VD) is a dementia syndrome caused by brain tissue damage caused by cerebrovascular factors, a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D493/04A61P9/10A61P25/00A61P25/28
CPCC07D493/04A61K31/352A61P9/10A61P25/00A61P25/28C07D311/86
Inventor 占扎君单伟光陈艳舒仁欢王建伟马列峰
Owner 上海如凌生物医药有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com